Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Current Deferred Revenue (2025)

Verrica Pharmaceuticals has reported Current Deferred Revenue over the past 1 years, most recently at $782000.0 for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $782000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $782000.0 (changed N/A YoY), and the annual figure for FY2025 was $782000.0, changed.
  • Current Deferred Revenue for Q4 2025 was $782000.0 at Verrica Pharmaceuticals, down from $1.6 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for VRCA hit a ceiling of $1.6 million in Q3 2025 and a floor of $481000.0 in Q2 2025.